Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Webcast: Navigating new frontiers: Ways to find space in the future RA market

April 9, 2019 | Pharma, Webcast, healthcare, rheumatoid arthritis 

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Article: From KOLs to KOIs – How to identify and engage the new healthcare influencers

Paul Reed and Basil Feilding investigate a new breed of KOLs with online influence and explain why pharma needs to join the conversation.

New syndicated patient reports –

Living with Uterine Fibroids and Endometriosis US 2022

Webcast: From perceptions to prescribing: Combining forces with next-generation tracking and benchmarking to accelerate brand performance

In this webcast we demonstrate RP and STEM's integrated approaches which gives clients the level of insights they need to accelerate brand performance.

EVOKE MIND+MATTER BOLSTERS SENIOR TEAM WITH TRIO OF STRATEGIC HIRES

*Mohinder Mann joins as Associate Medical Director *Nicole Moores joins as Associate Director, Pharma & Lifesciences *Sharron Woods joins as Associate Director, Animal Health Evoke Mind+Matter has continued to strengthen...

Animation: Living With

The journey from the patient's perspective

Infographic: Therapy Watch Lupus

Download our latest infographic, which offers an introduction to the real-world patient insights collected by our Therapy Watch Lupus study.

Article: Getting their lives back: Improving options for people with Lupus

Head of Therapy Watch, Helen Parfitt and Head of Living With, Mariel Metcalfe, investigate Lupus from the perspective of both healthcare professionals and patients using data from our syndicated products.

Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021

Evoke KYNE took home the Communiqué Communications Consultancy of the Year award at the 2021 Communiqué Awards held on 1 September at the Grosvenor House hotel in London.David Kyne, CEO, Evoke KYNE said:...

Michael Grela Elected President of the Society for Health Communication

February 8, 2022 – Michael Grela, Evoke KYNE’s EVP, Head of Reputation and Social Impact, has been elected President of the Society for Health Communication, a member-driven organization working to advance the science...

Evoke Kyne Appoints Maureen Byrne to President and Promotes Four Executive Leaders

New York, April 27, 2022 – Evoke KYNE, an award-winning health communications agency, today announced the appointment of Maureen Byrne to President. Byrne will assume global leadership responsibilities from David Kyne including management of its...